Migrainous vertigo responsive to intravenous methylprednisolone: case reports.
Migrainous vertigo (MV) is a newer evolving concept in which vertigo is causally related to migraine. We report 4 patients with MV. Episodes of severe MV of more than 1-day duration were successfully terminated by intravenous methylprednisolone (IV MPS) in 2 patients. Two other patients who had attacks of MV almost daily also showed complete response to IV MPS.
Prakash
Sanjay
S
Department of Neurology, Medical College, Baroda, Gujarat, India.
Shah
Nilima D
ND
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000927:Anticonvulsants / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008881:Migraine Disorders / Q000150:complications*; D009325:Nausea / Q000209:etiology; D020795:Photophobia / Q000209:etiology; D016896:Treatment Outcome; D014635:Valproic Acid / Q000627:therapeutic use; D014717:Vertigo / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D014635:Valproic Acid; D008775:Methylprednisolone